Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
ApexOnco Front Page
Recent articles
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
Full data from Edge-Gastric are presented at ESMO.
The first TUB-040 data come just after Tubulis raised €308m.
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
